CureVac (NASDAQ:CVAC) | WebDisclosure

PRESS RELEASE

published on 09/12/2024 at 12:57, 2 months 9 days ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 2 months 12 days ago

CureVac présentera les premières données cliniques du vaccin contre le cancer du glioblastome CVGBM au congrès ESMO 2024

CureVac Vaccin À ARNm Glioblastome Données Cliniques Congrès De L'ESMO
BRIEF

published on 09/09/2024 at 13:05, 2 months 12 days ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 2 months 12 days ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress
BRIEF

published on 08/15/2024 at 13:11, 3 months 6 days ago

CureVac Reports Second Quarter and First Half 2024 Financial Results and Business Developments

Financial Results Oncology CureVac MRNA Platform GSK Partnership
BRIEF

published on 08/15/2024 at 13:11, 3 months 6 days ago

CureVac publie ses résultats financiers et ses développements commerciaux pour le deuxième trimestre et le premier semestre 2024

Résultats Financiers Oncologie CureVac Plateforme D'ARNm Partenariat GSK
BRIEF

published on 08/15/2024 at 13:08, 3 months 6 days ago

CureVac fait progresser le vaccin candidat contre le cancer CVGBM vers la partie B de l'étude de phase 1

Étude Clinique CureVac Vaccin À ARNm Glioblastome CVGBM
BRIEF

published on 08/15/2024 at 13:08, 3 months 6 days ago

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study

Clinical Study CureVac MRNA Vaccine Glioblastoma CVGBM
PRESS RELEASE

published on 08/15/2024 at 13:06, 3 months 6 days ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
CureVac announces Q2 2024 financial results, new agreement with GSK, strategic workforce reduction, milestone payment, board appointments, CFO transition, and cash position update

Financial Results Business Update Q2 2024 CureVac GSK Agreement
BRIEF

published on 08/15/2024 at 13:05, 3 months 6 days ago

CureVac nomme le Dr Mehdi Shahidi, oncologue et expert en développement de médicaments, au conseil de surveillance

Conseil De Surveillance Oncologie CureVac Technologie De L'ARNm Dr Mehdi Shahidi

Published on 11/21/2024 at 16:01, 18 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 19 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 19 minutes ago

Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 19 minutes ago

Isaac Ullatil Joins Wellstack Board of Directors
Published on 11/21/2024 at 15:30, 49 minutes ago

CLS Health Opens New Comprehensive Care Clinic in Sugar Creek

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 19 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 38 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 55 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 56 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 57 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 9 hours 21 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 21 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 21 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 12 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 20 hours 59 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE

News